Biotechnology has been the only industry to launch initial public offerings in the US in 2016, and based on the performance of the four drug makers' stocks so far, they may be the only biotech firms to go public this year.
Biotechnology has been the only industry to launch initial public offerings in the US in 2016, and based on the performance of the four drug makers' stocks so far, they may be the only biotech firms to go public this year.
At least one biotech company already has opted for venture capital rather than stock market backing after AveXis Inc. and...
Create an account to read this article
Already a subscriber?
Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.
Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
